We are live on ! Find out more
PNT

POINT Biopharma Global Inc. Common Stock
PNT

Delisted

PNT was delisted on the 26th of December, 2023.

Back to rankings

125 hedge funds and large institutions have $411M invested in POINT Biopharma Global Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 51 increasing their positions, 38 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

34% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 38

4% less funds holding

Funds holding: 130 → 125 (-5)

28% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 18

28% less capital invested

Capital invested by funds: $571M → $411M (-$160M)

41% less call options, than puts

Call options by funds: $1.55M | Put options by funds: $2.64M

100% less funds holding in top 10

Funds holding in top 10: 3 → 0 (-3)

Holders
125
Holders Change
-5
Holders Change %
-3.85%
% of All Funds
1.98%
Holding in Top 10
–
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-100%
% of All Funds
–
New
13
Increased
51
Reduced
38
Closed
18
Calls
$1.55M
Puts
$2.64M
Net Calls
-$1.08M
Net Calls Change
-$473K

Top Buyers

Rank Fund Capital Flow
1
BG
Bellevue Group
Switzerland
+$9.1M
2
Millennium Management
Millennium Management
New York
+$7.08M
3
Charles Schwab
Charles Schwab
California
+$3.71M
4
American Century Companies
American Century Companies
Missouri
+$3.46M
5
PHS
PFM Health Sciences
California
+$2.61M

Top Sellers

Rank Fund Capital Flow
1
APM
Avidity Partners Management
Texas
-$15.1M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$9.48M
3
BBA
Baker Bros. Advisors
New York
-$7.64M
4
Goldman Sachs
Goldman Sachs
New York
-$5.96M
5
VCIM
Velan Capital Investment Management
Georgia
-$3.11M
Name Holding Trade Value Shares
Change 		Change in
Stake
JAM
26
Jupiter Asset Management
United Kingdom
$3.5M +$1.72M +207,277 +65%
Arrowstreet Capital
27
Arrowstreet Capital
Massachusetts
$3.49M +$2.33M +279,801 +115%
NCM
28
Nantahala Capital Management
Connecticut
$3.48M -$424K -51,000 -9%
Janus Henderson Group
29
Janus Henderson Group
United Kingdom
$2.61M +$827K +99,548 +34%
PAMP
30
Polar Asset Management Partners
Ontario, Canada
$2.53M +$1.18M +142,400 +60%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$2.22M +$29.9K +3,595 +1%
Renaissance Technologies
32
Renaissance Technologies
New York
$2.18M +$1.13M +136,296 +71%
Bank of America
33
Bank of America
North Carolina
$2.05M +$1.24M +149,604 +95%
EHI
34
Eagle Health Investments
Connecticut
$2.04M – – –
William Blair & Company
35
William Blair & Company
Illinois
$1.67M -$125K -15,002 -6%
BBA
36
Baker Bros. Advisors
New York
$1.67M -$7.64M -919,135 -79%
Goldman Sachs
37
Goldman Sachs
New York
$1.61M -$5.96M -717,388 -75%
Rafferty Asset Management
38
Rafferty Asset Management
New York
$1.49M +$228K +27,436 +14%
Connor, Clark & Lunn Investment Management (CC&L)
39
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1.43M -$469K -56,413 -21%
D.E. Shaw & Co
40
D.E. Shaw & Co
New York
$1.12M +$248K +29,781 +22%
RhumbLine Advisers
41
RhumbLine Advisers
Massachusetts
$982K +$17.5K +2,101 +1%
Barclays
42
Barclays
United Kingdom
$949K +$225K +27,030 +23%
Swiss National Bank
43
Swiss National Bank
Switzerland
$930K +$20.8K +2,500 +2%
BFS
44
Baskin Financial Services
Ontario, Canada
$887K – – –
Invesco
45
Invesco
Georgia
$887K +$583K +70,196 +112%
AllianceBernstein
46
AllianceBernstein
Tennessee
$870K – – –
Morgan Stanley
47
Morgan Stanley
New York
$855K -$627K -75,466 -37%
Qube Research & Technologies (QRT)
48
Qube Research & Technologies (QRT)
United Kingdom
$784K +$750K +90,230 +330%
MAM
49
Martingale Asset Management
Massachusetts
$677K +$183 +22 +0%
Citigroup
50
Citigroup
New York
$665K +$149K +17,913 +22%
1
2
3 4 5

PNT Hedge Fund Activity: Q3 2023 in Review

125 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in POINT Biopharma Global Inc. Common Stock (PNT) for Q3 2023, worth a combined $411M — down 28% from $571M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of PNT and 13 opened new positions — a net loss of 5 holders — while 38 trimmed existing stakes and 51 added.

The largest buyer was Bellevue Group, adding an estimated $9.1M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $15.1M sold.

  • 125 institutional investors held POINT Biopharma Global Inc. Common Stock (PNT) as of Q3 2023, down from 130 in Q2 2023.
  • Funds reported $411M of POINT Biopharma Global Inc. Common Stock stock for Q3 2023, down 28% quarter-over-quarter.
  • 13 funds opened new POINT Biopharma Global Inc. Common Stock positions in Q3 2023 and 18 closed out, a net change of -5 holders.
  • The largest POINT Biopharma Global Inc. Common Stock buyer in Q3 2023 was Bellevue Group, an estimated $9.1M added.
  • The largest POINT Biopharma Global Inc. Common Stock seller in Q3 2023 was Avidity Partners Management, an estimated $15.1M sold.

Based on aggregated 13F filings for Q3 2023.